# Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

> **NCT06128070** · PHASE2 · RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 40 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Chest Computed Tomography
- **PROCEDURE:** Echocardiography
- **PROCEDURE:** Hematopoietic Cell Transplantation
- **DRUG:** Methotrexate
- **PROCEDURE:** Multigated Acquisition Scan
- **DRUG:** Ruxolitinib Phosphate
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT06128070
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-16
- **Primary completion:** 2030-11-22
- **Final completion:** 2030-11-22
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06128070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06128070, "Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06128070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*